RxDoctor Payments Data

Lisa Massie, MD

Cardiovascular Disease · New Britain, CTNPI 1053366757

Payments from drug & device makers

$589in general payments, 2019–2025

Across 33 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$224
  • Novartis$135
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$73
  • E.r. Squibb & Sons, L.L.C.$50
  • Pfizer$36
  • Amarin Pharma, Inc.$35
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$589100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$589 in reported general payments places this provider in the 30th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$166,338
Medicare patients
2,239
Services billed
3,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$103,558
EntrestoSacubitril/Valsartan34$28,259
XareltoRivaroxaban13$14,632
FarxigaDapagliflozin Propanediol21$14,295
Praluent PenAlirocumab19$8,731
Repatha SureclickEvolocumab13$8,141
Metoprolol Succinate165$3,226
Rosuvastatin Calcium102$2,646
Ezetimibe19$1,131
Isosorbide Mononitrate ErIsosorbide Mononitrate28$1,003
Atorvastatin Calcium45$889
Amlodipine Besylate120$786
Losartan Potassium64$725
Lisinopril87$671
Spironolactone40$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$103,558112 claims
NovartisEntresto$135$28,25934 claims
Johnson & JohnsonXarelto$224$14,63213 claims
AstraZenecaFarxiga$19$14,29521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →